Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity.

Item

http://www.wikidata.org/entity/Q39178828

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Delta-9-Tetrahydrocannabinol/C ...... Sclerosis-Related Spasticity.

@en

Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray

@nl

type

Item

label

Delta-9-Tetrahydrocannabinol/C ...... Sclerosis-Related Spasticity.

@en

Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray

@nl

prefLabel

Delta-9-Tetrahydrocannabinol/C ...... Sclerosis-Related Spasticity.

@en

Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray

@nl

P1476

Delta-9-Tetrahydrocannabinol/C ...... Sclerosis-Related Spasticity.

@en

P2860

Human cannabinoid pharmacokinetics

Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis

Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis

Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study.

Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.

Falls in people with multiple sclerosis compared with falls in healthy controls.

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).

P2888

s40265-017-0720-6

P304

563-574

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-017-0720-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gillian M Keating

P577

2017-03-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28293911

http://www.w3.org/2001/XMLSchema#string

P921

tetrahydrocannabinol

cannabidiol

cannabinoids